Reply: Cost of Therapies in Acute Coronary Syndromes: A Relevant Factor Not Reflected in the Trials

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43916754" target="_blank" >RIV/00216208:11120/18:43916754 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/18:N0000127

Result on the web

<a href="https://doi.org/10.1016/j.jacc.2018.04.002" target="_blank" >https://doi.org/10.1016/j.jacc.2018.04.002</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.jacc.2018.04.002" target="_blank" >10.1016/j.jacc.2018.04.002</a>

Result language

angličtina

Original language name

Reply: Cost of Therapies in Acute Coronary Syndromes: A Relevant Factor Not Reflected in the Trials

Original language description

Patient participation in covering the cost associated with medical therapy after acute myocardial infarction (AMI) is a factor that limits the use of evidence-based recommendations in every day patient care. The significance of this factor is further exacerbated when long-term therapy is required. Nonadherence to recommended guidelines negatively influences patient prognosis. In long-term dual antiplatelet therapy (DAPT), within the scope of secondary prevention following MI, ignoring recommendations for the use of the new P2Y12 inhibitors, prasugrel and ticagrelor (and using clopidogrel), as well as shortening therapy duration to &lt;12 months, can be considered as not complying with the guidelines (especially when there are no contradictions or high bleeding risk). Recognizing the importance of out-of-pocket costs has led to initiatives that further proved that adherence to therapy increases after elimination of copayment. The ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) trial documented greater compliance with the use of the new P2Y12 inhibitors and longer DAPT duration when out-of-pocket costs were compensated. The trial also pointed to the complexity of the adherence to therapy issue. Nearly 1 in 3 patients in the intervention arm did not use the copayment reduction option. The most important initial intervention will remain the decision to discuss the importance of medication adherence with our patients. Dr. Lozano and colleagues commented on the communication gap that exists between patients and physicians relative to the cost the patient will incur while using a prescribed medication.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of the American College of Cardiology

ISSN

0735-1097

e-ISSN

—

Volume of the periodical

71

Issue of the periodical within the volume

23

Country of publishing house

US - UNITED STATES

Number of pages

2

Pages from-to

2711-2712

UT code for WoS article

000434924500021

EID of the result in the Scopus database

2-s2.0-85047544321